The problem
Patients wait weeks for specialty drugs while practices fight insurer paperwork; a third never get the first dose
What they do
AI agents that handle prior auths, appeals, copay help and pharmacy routing for prescriptions
Traction $50M+ ARR run-rate (est.; $10M end-2025, ~5x by May 2026); 9 of top 15 biopharma; 1/3 of US dermatologists
Hiring trend
- Open roles
- 54
- Ops roles
- 4
- Headcount
- ~210-230
Headcount ~100 (May 2026, company) to ~210-230 (Sep 2026, LinkedIn/Crustdata); plans to more than double in 2026; 53 open roles, all NYC
Hiring in
- New York
Latest news
Sep 2026
Raised $150M Series C led by Bain Capital Ventures at $3B valuation, tripling in four months ↗Funding
- Last round
- $150M
- Stage
- Series C
- Date
- Sep 2026
Led by Bain Capital Ventures (Series C); Thrive Capital, Accel, General Catalyst (earlier rounds)
- Hiring+254 open roles on the live job board (30+ roles = +2)
- Funding recency+2Series C · $150M, Sep 2026 (1 month ago): 6 months or less = +1.5, $100M+ round +0.5
- Traction+1.5Strong growth: $50M+ ARR run-rate (est.; $10M end-2025, ~5x by May 2026); 9 of top 15 biopharma; 1/3 of US dermatologists
- Red flags0None found in the last 24 months
- Total5.52 + 2 + 1.5 − 0 = 5.5 → Sprint (4.75 or more)
Distance (Half) is a separate read on how long the lead can last. It doesn't change the score.
Distance
Half · edge: grows with users
Fast-rising leader in AI medication access with broad adoption (thousands of practices, 1/3 of US dermatology, 9 of top 15 biopharma) and a two-sided network that learns from every case; still small next to incumbent CoverMyMeds (McKesson), and the free-for-providers model leans on biopharma revenue.
Sources: Fierce Healthcare: Forus $150M Series C at $3B (Sep 2026) ↗ · Forbes: Forus hits $1B valuation, ARR >$10M end-2025 and ~5x since (May 2026) ↗ · Forus: Series C announcement (Sep 2026) ↗
Last checked Oct 25, 2026